<?xml version="1.0" encoding="UTF-8"?>
<p>HEV 239 (Hecolin; Xiamen Innovax Biotech, Xiamen, China), which was approved by China’s State Food and Drug Administration (SFDA) in December 2011, is the world’s first commercial vaccine against HEV infection 
 <xref rid="pone.0087600-Park1" ref-type="bibr">[13]</xref>. The results of a Phase III trial in China involving 11,165 healthy men and women aged 16–65 years showed a protective efficacy of 100% and no unexpected side effects in the general population 
 <xref rid="pone.0087600-Zhu1" ref-type="bibr">[14]</xref> and pregnant women 
 <xref rid="pone.0087600-Wu1" ref-type="bibr">[15]</xref>. In the present study, we evaluated the efficacy of the HEV 239 vaccine in protecting rabbits against homologous and heterologous HEV infections, aiming to examine whether HEV 239 could serve to manage HEV transmission from its animal reservoirs.
</p>
